
                     -: a regulator of chemo-sensitivity through suppression of the RAD51-homologous recombination axis by unknown
Liu et al. Chin J Cancer  (2015) 34:44 
DOI 10.1186/s40880-015-0049-z
COMMENTARY
miR-506: a regulator of chemo-sensitivity 
through suppression of the RAD51-homologous 
recombination axis
Guoyan Liu1*, Fengxia Xue1 and Wei Zhang2*
Abstract 
Ovarian carcinoma is the most lethal gynecologic malignancy. Resistance to platinum is considered the major prob-
lem affecting prognosis. Our recent study established that microRNA-506 (miR-506) expression was closely associated 
with progression-free survival and overall survival in two independent patient cohorts totaling 598 epithelial ovar-
ian cancer cases. Further functional study demonstrated that miR-506 could augment the response to cisplatin and 
olaparib through targeting RAD51 and suppressing homologous recombination in a panel of ovarian cancer cell lines. 
Systemic delivery of miR-506 in an orthotopic ovarian cancer mouse model significantly augmented the cisplatin 
response, thus recapitulating the clinical observation. Therefore, miR-506 plays a functionally important role in homol-
ogous recombination and has important therapeutic value for sensitizing cancer cells to chemotherapy, especially in 
chemo-resistant patients with attenuated expression of miR-506.
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Background
Epithelial ovarian cancer remains the most lethal gyneco-
logic malignancy [1, 2]. The majority of cases are diag-
nosed at an advanced stage, with a 5-year survival rate 
of only 30%–40% [3]. Debulking surgery and platinum-
based chemotherapy play important roles in the man-
agement of epithelial ovarian cancer, whereas acquired 
resistance to platinum is considered a major factor in dis-
ease relapse.
Recently, it has been reported that microRNAs (miR-
NAs), which are single-stranded, non-coding endog-
enous RNAs, play a crucial role in regulating drug 
resistance. Possible mechanisms in regulating drug resist-
ance involve the regulation of cell cycle distribution, drug 
transport, DNA repair, epithelial-mesenchymal transition 
(EMT), and apoptosis pathways. Platinum-based drugs 
can form intra- and inter-strand adducts with DNA, 
which cause DNA double-strand breaks and trigger 
DNA damage and repair pathways. Thus, enhancement 
of the DNA repair system plays a major role in platinum 
resistance. Homologous recombination (HR) is a criti-
cal pathway for DNA double-strand break repair; cells 
with compromised HR machinery are highly sensitive to 
DNA-damaging drugs [4].
Our recent investigation of The Cancer Genome Atlas 
(TCGA) database network for high-grade serous ovarian 
carcinoma showed that microRNA-506 (miR-506) expres-
sion was associated with an increased response to therapy 
and prolonged progression-free survival (PFS) and overall 
survival (OS). This result was confirmed in another clini-
cally annotated genomics dataset (Bagnoli) [5]. Our previ-
ous studies have demonstrated that miR-506 can inhibit 
EMT and proliferation by targeting the snail family zinc 
finger 2 (SNAL2) and cyclin-dependent kinase 4/6-Fork-
head box protein M1 (CDK4/6-FOXM1) axes, respec-
tively [6–8]. After overexpressing miR-506 in a panel of 
ovarian cancer cell lines, we analyzed the down-regulated 
genes via a microarray and observed a decrease in RAD51 
levels. When we used the miRNA target prediction algo-
rithm TargetScan 6.0 (Whitehead Institute for Biomedical 
Research, Cambridge, MA, USA), we found that RAD51 
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had one predicted binding site for miR-506. We next per-
formed a set of functional validation experiments using 
reporter gene assays. We found that miR-506 suppressed 
the reporter activity linked to the 3′- untranslated region 
(UTR) of RAD51 that contains the predicted binding site. 
The use of control miRNA or removal of the binding site 
did not produce the same regulation exhibited by miR-
506. These results showed that RAD51 is a direct target 
of miR-506. Furthermore, the inverse association between 
miR-506 and RAD51 expression was confirmed in three 
different cohorts of clinical samples (the TCGA, Bagnoli, 
and Tianjin cohorts).
We next sought to understand how important the 
regulation of RAD51 is to the drug response and sur-
vival of serous ovarian cancer patients. RAD51 is known 
to be a critical component of the HR-mediated double-
strand DNA break repair machinery, and during this 
process, RAD51 assembles onto single-stranded DNA 
as a nucleoprotein filament and catalyzes the exchange 
of homologous DNA sequences [9]. Because RAD51 
is an integral component of the cellular DNA dam-
age response, RAD51 suppression can sensitize cancer 
cells to DNA-damaging drugs [10–13]. By performing a 
homology-directed repair assay, we found that transfec-
tion with a miR-506 mimic or treatment with small inter-
fering RNA (siRNA) against RAD51 significantly reduced 
the HR efficiency. In addition, ectopic overexpression of 
miR-506 led to higher residual DNA damage (as shown 
by single-cell gel electrophoresis) and less RAD51 foci 
formation (as shown by immunofluorescence microscopy 
imaging) as compared with controls after cisplatin treat-
ment, confirming the defect in HR.
HR-deficient cells are sensitive to DNA-damaging 
drugs and poly(ADP) ribose polymerase (PARP) inhibi-
tors, and this effect has been termed synthetic lethality 
[14, 15]. Recent studies have demonstrated that breast 
cancer early onset 2 (BRCA2) mutations, and to a lesser 
extent breast cancer early onset 1 (BRCA1) mutations/
methylation, are associated with improved survival and 
responses to therapy in serous ovarian cancer patients 
[16–18]. We next examined the effect of miR-506 on 
the sensitivity to cisplatin and olaparib (a PARP inhibi-
tor) in ovarian cancer in vitro and in vivo and found that 
miR-506-transfected cells were more sensitive to cispl-
atin or olaparib than control cells in both 3-(4,5-dime-
thyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide 
(MTT) and clonogenic survival assays. Conversely, 
anti-miR-506 locked nucleic acid (LNA) transfection 
enhanced RAD51 expression and induced resistance to 
cisplatin and olaparib in cells. Moreover, the effect of 
miR-506 on cisplatin and olaparib sensitivity was rescued 
by overexpressing RAD51 without its 3′-UTR, suggest-
ing that miR-506-mediated sensitivity to cisplatin and 
olaparib is the result of the suppression of RAD51 expres-
sion. Consistent with the results of in vitro experiments, 
delivery of miR-506 incorporated in 1,2-dioleoyl-sn-
glycerol-3-phosphatidylcholine (DOPC) nanoliposomes 
effectively enhanced the effect of cisplatin and olaparib in 
an orthotopic ovarian cancer model.
In summary, our recent investigations have revealed 
that miR-506 can enhance the sensitivity to cisplatin and 
PARP inhibitors through suppression of the RAD51-
HR axis. Furthermore, nanoparticle delivery of miR-506 
enhanced the effects of cisplatin and olaparib in ortho-
topic ovarian cancer models. Thus, miR-506 not only is 
a robust clinical marker for the chemotherapy response 
and survival of serous ovarian cancer patients but also 
has important therapeutic value in sensitizing cancer 
cells to chemotherapy. This new discovery shows that 
miR-506 combined with DNA-damaging agent treatment 
may benefit patients with high-grade serous ovarian car-
cinoma. Taken together with the findings of our previous 
study on this small molecule, we have shown that miR-
506 has multiple therapeutic effects on regulating the 
biological behavior of cancer cells (Fig. 1).
Fig. 1 A summary of the therapeutic role of microRNA-506 (miR-
506). miR-506, located on Xq27.3, is down-regulated by methylation. 
miR-506 directly targets RAD51, cyclin-dependent kinase 4/6-Fork-
head box protein M-1 (CDK4/6-FOXM1), and snail family zinc finger 2 
(SNAI2), thus repressing homologous recombination (HR), promoting 
cellular senescence, and suppressing epithelial-mesenchymal transi-
tion (EMT), respectively. As a result, miR-506 sensitizes cancer cells 
to chemotherapy and inhibits cell proliferation and EMT-mediated 
metastasis
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